End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.59 CNY | +1.12% |
|
+4.10% | -46.03% |
15/05 | Mingyue Optical Lens Co.,Ltd. Approves Cash Dividend for the Year 2023 | CI |
22/04 | Mingyue Optical Lens Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-46.03% | 624M | - | ||
+10.13% | 98.57B | B | ||
+21.48% | 43.85B | B | ||
-8.69% | 17.2B | B- | ||
-30.12% | 1.95B | D+ | ||
+22.07% | 1.16B | - | ||
+73.37% | 675M | - | - | |
-9.39% | 653M | - | ||
-43.68% | 620M | B- | ||
+30.18% | 546M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301101 Stock
- Ratings Mingyue Optical Lens Co.,Ltd.